Trial Profile
A Phase 2a, Open-Label, Study Evaluating the Safety and Anti-Viral Activity of ARB-001467 in Non-Cirrhotic, HBeAg-Negative Subjects with Chronic HBV Infection (Genotype A or B) in Combination with PEG-IFN α-2a and Tenofovir Disoproxil Fumarate
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 18 Dec 2020
Price :
$35
*
At a glance
- Drugs ARB 1467 (Primary) ; Peginterferon alfa-2a (Primary) ; Tenofovir disoproxil fumarate (Primary)
- Indications Hepatitis B
- Focus Proof of concept; Therapeutic Use
- Sponsors Arbutus Biopharma
- 22 May 2020 This trial has been completed in Poland, according to the European Clinical Trials Database record.
- 08 Mar 2019 According to an Arbutus Biopharma media release, company has discontinued development of ARB-1467. Results from the ARB-1467 clinical trials confirmed the potential therapeutic value of an RNAi agent and informed the development of next-generation RNAi agent, AB-729.
- 07 Mar 2019 Status changed from recruiting to discontinued, according to an Arbutus Biopharma media release.